DE60137721D1 - Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs - Google Patents

Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs

Info

Publication number
DE60137721D1
DE60137721D1 DE60137721T DE60137721T DE60137721D1 DE 60137721 D1 DE60137721 D1 DE 60137721D1 DE 60137721 T DE60137721 T DE 60137721T DE 60137721 T DE60137721 T DE 60137721T DE 60137721 D1 DE60137721 D1 DE 60137721D1
Authority
DE
Germany
Prior art keywords
lyn
inhibitors
treatment
prostate cancer
signal transduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60137721T
Other languages
English (en)
Inventor
Shmuel Ben-Sasson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Medical Center Corp
Original Assignee
Childrens Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center Corp filed Critical Childrens Medical Center Corp
Application granted granted Critical
Publication of DE60137721D1 publication Critical patent/DE60137721D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
DE60137721T 2000-12-11 2001-12-11 Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs Expired - Fee Related DE60137721D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/735,279 US20020019346A1 (en) 1997-05-21 2000-12-11 Treatment of prostate cancer by inhibiting lyn tyrosine kinase
PCT/US2001/047444 WO2002047710A2 (en) 2000-12-11 2001-12-11 Use of inhibitors of lyn-associated signal transduction (last) in the treatment of prostate cancer

Publications (1)

Publication Number Publication Date
DE60137721D1 true DE60137721D1 (de) 2009-04-02

Family

ID=24955113

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60137721T Expired - Fee Related DE60137721D1 (de) 2000-12-11 2001-12-11 Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs

Country Status (6)

Country Link
US (3) US20020019346A1 (de)
EP (1) EP1366063B1 (de)
AT (1) ATE423129T1 (de)
AU (1) AU2002228913A1 (de)
DE (1) DE60137721D1 (de)
WO (1) WO2002047710A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215528A1 (en) * 2001-08-10 2005-09-29 Shuichi Furuya Gnrh agonist combination drugs
EP1509545B8 (de) * 2002-05-31 2010-10-13 Merck Serono Biodevelopment SAS Homotrimerer, erweiterter globulärer kopf von obg3 und verwendungen davon
WO2005032595A2 (en) * 2003-04-23 2005-04-14 Georgetown University Methods and compositions for the inhibition of stat5 in prostate cancer cells
JP5113752B2 (ja) 2005-08-22 2013-01-09 メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド Ｌｙｎキナーゼの活性を調節し、関連する疾患を治療するための方法および製剤
CN101686686A (zh) * 2007-02-20 2010-03-31 梅里奥尔医药I公司 鉴别Lyn激酶激活剂的方法
MX2009009693A (es) * 2007-07-23 2009-10-07 Melior Discovery Inc Metodos para activar irs-1 y akt.
US8552184B2 (en) * 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
CA3059432A1 (en) 2017-04-10 2018-10-18 Melior Pharmaceuticals I, Inc. Compositions comprising a lyn kinase activator and a trpms agonist

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2131389A1 (en) * 1992-03-02 1993-09-16 John M. Maraganore Thrombin receptor antagonists
US5508383A (en) * 1994-03-09 1996-04-16 Tap Holdings Inc. Cyclic peptide LHRH antagonists
US6723694B1 (en) * 1997-05-21 2004-04-20 The Children's Medical Center Corp. Short peptides which selectively modulate intracellular signalling
AU756838B2 (en) * 1998-03-04 2003-01-23 Bristol-Myers Squibb Company Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors

Also Published As

Publication number Publication date
EP1366063A2 (de) 2003-12-03
US20020151497A1 (en) 2002-10-17
US20020019346A1 (en) 2002-02-14
ATE423129T1 (de) 2009-03-15
US20080045460A1 (en) 2008-02-21
WO2002047710A3 (en) 2003-04-24
WO2002047710A2 (en) 2002-06-20
EP1366063B1 (de) 2009-02-18
AU2002228913A1 (en) 2002-06-24

Similar Documents

Publication Publication Date Title
NO995544D0 (no) Forbindelser og metoder for inhibering av ekspresjonen av VCAM-1
ATE269295T1 (de) Btk inhibitoren und verfahren zur identifizierung und verwendung
DE602004015811D1 (de) Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
DE60142590D1 (de) Verwendung von Botulinum Toxin zur Behandlung von post-operative Schmerzen
ATE372341T1 (de) Inhibitoren von mitotischem kinesin
ATE295735T1 (de) Verwendung von interleukin-6 antagonisten zur behandlung von oestrogen-abhängigen krebs
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
DE69722621D1 (de) Inhibierung von dns reparatur zur erhöhung der sensitivität für p53-vermittelte suppression
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
DE60137721D1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
DE602005010258D1 (de) Behandlung von ballastwasser
ATE333869T1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
DE60123138D1 (de) Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen
DE602004022423D1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
ATE332970T1 (de) Verfahren und zusammensetzungen zur hemmung von neoplastischem zellwachstums
DE50311665D1 (de) Guanidinophenylalanin-verbindungen als urokinase-inhibitoren
ATE432359T1 (de) Modulation der s6-kinaseaktivität zur behandlung von adipositas
DE60312988D1 (de) Verwendung von einem chrysanthellum indicum extrakt zur behandlung der akne rosacea
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen
ATE486598T1 (de) Kinase inhibitoren und deren verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee